Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsMario H. Skiadopoulos, Peter L. Collins, Brian R. Murphy, Alexander C. Schmidt
Estimating the term…
Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
A chimeric, infectious human-bovine chimeric parainfluenza virus (PIV) comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a partial or complete PIV background genome or antigenome of a human PIV3 (HPIV3) combined with a M gene or genome segment(s) thereof of a bovine PIV to form a human-bovine chimeric PIV genome or antigenome.
Dependencies are inferred from the claim text.